SCHEMBL6501075

SCHEMBL6501075

Cc1ccc(-c2ccc(C)cc2C(=O)Nc2ccc(NCCc3csc(N)n3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
TP53 P04637 4/20 0.41
MAPK14 Q16539 1/20 0.41
LMNA P02545 1/20 0.41
STAT1 P42224 2/20 0.40
KDM1A O60341 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
LCK P06239 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490142 0.94 POLB (0.43) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6499252 0.93 POLB (0.47) MAPTKDM4ETP53LMNASMN1; SMN2
SCHEMBL6489328 0.92 GCGR (0.42) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6793046 0.90 NPC1 (0.47) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6502168 0.90 NPC1 (0.51) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6498180 0.87 GCGR (0.50) MAPTTP53LMNAPOLB
SCHEMBL6502572 0.86 SMN1; SMN2 (0.60) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6492802 0.86 POLB (0.47) MAPTKDM4ETP53LMNASMN1; SMN2
SCHEMBL6499843 0.85 SMN1; SMN2 (0.47) RAB9ANPC1MAPTALDH1A1KDM4E
SCHEMBL6492232 0.84 CYP3A4 (0.41) RAB9ANPC1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 RAB9A 4382/4885NPC1 100/4885MAPT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.